Author: Emboline, Inc.

Posted Date:

March 30, 2026

Emboline Announces Positive Pivotal PROTECT H2H Trial Results for Emboliner® Presented as a Late-Breaking Clinical Trial at ACC 2026

Emboline, Inc.

March 30, 2026
Emboline, Inc. Secures $20 Million in Growth Capital from Trinity Capital Inc. to Support Commercialization of the Emboliner® Embolic Protection System to Minimize Stroke Risk From TAVR

Emboline, Inc.

March 11, 2026